Swiss Archives of Neurology Psychiatry and Psychotherapy
May 18, 2024
Helena Aicher, Peter Gasser
17 citations
Switzerland's early contributions to the 'psychedelic renaissance', the revival of psychedelic science starting in the early 21st century, might be particularly noteworthy given the growing global interest in using psychedelics for research and therapy.In 2023, the Swiss Interest Group for Psychedelic-assisted Therapy was established to provide a clear and widely accepted framework for work...
Nervenheilkunde
May 14, 2024
Jörg Daumann, Uwe Herwig
ZUSAMMENFASSUNG Die Anwendung von Psychedelika in der Psychotherapie wirft erhebliche ethische, soziale und klinische Fragen auf. Gesundheitliche Risiken, Spezifika des Informed Consent, medialer Einfluss, die Rolle der Therapeuten, Sicherheitsaspekte und der rechtliche Status sind exemplarische Schlüsselbereiche. Auch in der wissenschaftlichen Evaluation der psychedelikaaugmentierten...
Neuropsychopharmacology
May 13, 2024
Conor H. Murray
MDMA-assisted psychotherapy has emerged as a potential treatment for psychiatric illnesses, with findings from clinical trials in the last decade demonstrating safety and efficacy in the treatment of posttraumatic stress disorder (PTSD), among other psychiatric indications. Earlier this year (2024), the Food and Drug Administration in the United States granted priority review for a new drug...
May 2, 2024
Prince Patel, Samrat Gollapudi, Brian Joseph Mathew et al.
Psychedelic-assisted psychotherapy (PAP) has shown promising therapeutic benefits for various psychiatric disorders, but the underlying neural mechanisms remain unclear. This study aimed to investigate the effects of psychedelics on brain connectivity patterns using functional magnetic resonance imaging (fMRI). A comprehensive literature search was conducted in PubMed and Google Scholar...
Journal of Psychoactive Drugs
May 2, 2024
Dave Rojas, Diane C Zelman, Alexander O Hauson et al.
2 citations
Black, Indigenous, and People of Color (BIPOC), and other minoritized populations are insufficiently represented in research on therapeutic psychedelics. This research was a phenomenological qualitative exploration of a culturally diverse (Hispanic, African American, Asian, Native American, biracial, or LGBTQIA+) and low-income sample of 15 individuals receiving ketamine-assisted psychotherapy...
EMBARK Psychedelic Therapy for Depression
April 23, 2024
Bill Brennan, Alex Belser
AbstractChapter 1 introduces the concept of psychedelic-assisted therapy (PAT) and the EMBARK psychedelic therapy model, a new approach to PAT and psychological support. The chapter serves as an orientation to the book, outlining its structure and intended audiences. It discusses the growing interest in psychedelic medicines for treating mental health disorders, particularly depression. The...
Journal of Psychopharmacology
April 23, 2024
Evan Cole Lewis, Alexandria Jaeger, Manesh Girn et al.
6 citations
Functional seizures (FS), the most common subtype of functional neurological disorder (FND), cause serious neurological disability and significantly impact quality of life. Characterized by episodic disturbances of functioning that resemble epileptic seizures, FS coincide with multiple comorbidities and are treated poorly by existing approaches. Novel treatment approaches are sorely needed....
Neuropsychopharmacology
April 23, 2024
Julia Colcott, Olivia Carter, Sally Meikle et al.
37 citations
Abstract Evidence suggests that MDMA-assisted psychotherapy (MDMA-AP) has therapeutic potential for treatment of psychiatric illness. We conducted the first comprehensive systematic review and meta-analysis of the side effects of MDMA-AP across indications. We also assessed the quality of side effects-reporting in published trials of MDMA-AP. PubMed, EMBASE, PsycINFO, MEDLINE and Cochrane...
Frontiers in Psychiatry
April 18, 2024
Gina Micciche, Andrew McMillan, Emily Coughlin et al.
4 citations
Introduction Patients with incurable illnesses often experience existential distress, profoundly impacting their well-being. Current medical approaches have limitations in addressing these burdens. Psilocybin, a promising psychedelic compound, may offer therapeutic benefits. This pilot survey study aimed to investigate the attitudes and openness toward psilocybin-assisted psychotherapy (PAT)...
Australian & New Zealand Journal of Psychiatry
April 16, 2024
Samuel P Hatfield, Nicollette Lr Thornton, Kayla Greenstien et al.
9 citations
Objectives: The Australian government recently rescheduled psilocybin and 3,4-methylenedioxymethamphetamine for limited clinical uses. This change has raised various regulatory concerns and challenges for the field of psychedelic-assisted therapy. To provide clarity, we aimed to comprehensively catalogue the matters relating to psychedelic-assisted therapy that are or could be regulated....